Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
$32.67
$0.68(1.60%)
At close: 4:00 PM EST
$32.67
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $50.71
Previous CloseN/A
Volume253.49K
Average Volume (3M)994.67K
Market Cap
$2.60B
Enterprise Value$2.27B
Total Cash (Recent Filing)$412.89M
Total Debt (Recent Filing)$39.65M
Price to Earnings (P/E)49.9
Beta1.25
Next Earnings
May 12, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.53
Shares Outstanding79,458,430
10 Day Avg. Volume783,755
30 Day Avg. Volume994,668
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit6.22
Enterprise Value/Ebitda27.27
Forecast
1Y Price Target
$43.25Price Target Upside32.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.66
Revenue Forecast (FY)$575.50M
Bulls Say, Bears Say
Bulls Say
Commercial TractionAnalyst points to sustained strong growth in Decipher and Afirma test volumes and notes that Veracyte's large urology sales channel supports rapid uptake for new bladder cancer testing.
Financial Strength And MarginsAnalyst emphasizes improving gross margins, stronger adjusted EBITDA, and a debt-free, cash-positive balance sheet that enable reinvestment into growth initiatives without weakening financial stability.
Pipeline LaunchesAnalyst highlights that planned launches of the TrueMRD minimal residual disease blood test and a Prosigna laboratory-developed test could materially accelerate revenue growth if commercialized and reimbursed.
Bears Say
Analyst SentimentAnalyst maintains a Hold rating pending clearer evidence of sustained long-term growth and successful commercialization of pipeline tests before recommending a Buy.
Execution And Operational RiskAnalyst cautions that ongoing product transitions, international expansion efforts, and partner integrations introduce execution risk that could delay revenue contributions from new tests.
ValuationAnalyst warns that the current valuation appears to price in much of the company's expected growth, limiting upside unless execution outperforms expectations.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $22.61 and its highest was $50.71 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.60B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is May 12, 2026 which is in 33 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Feb 25, 2026. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.409 by $0.121.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.33.
How many shares outstanding does Veracyte have?
Veracyte has 79,458,430 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.53 in its last earnings report, beating expectations of $0.409. Following the earnings report the stock price went up 8.483%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.25 (32.38% Upside)
$43.25 (32.38% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 821.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.12%
12-Months-Change
Fundamentals
Return on Equity
5.33%
Trailing 12-Months
Asset Growth
7.74%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a largely positive operational and financial story: robust revenue and volume growth, strong margins and cash generation, successful transition to a lower-cost transcriptome platform, substantial clinical evidence and data assets, and a clear product launch roadmap (TrueMRD and Prosigna) that sets up multi-year growth. Headwinds and risks were acknowledged—one-time prior-period collections (PPCs) amplified 2025 results and complicate comparability; planned investments and launch-related spending will temper margins in 2026; reimbursement timelines and near-term revenue contribution for new products (MRD, Prosigna, Percepta/NIGHTINGALE) remain uncertain. On balance, the highlights (top-line momentum, margins, cash, platform readiness, evidence generation, and pipeline) significantly outweigh the lowlights, which are mostly timing, one-time, or investment-related risks.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$43.25
▲(32.38% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
Currently, No data available
---